While there has been progress with using chimeric antigen receptor (CAR) T cells to treat multiple myeloma, these treatments aren’t ready for prime time, said Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.
While there has been progress with using chimeric antigen receptor (CAR) T cells to treat multiple myeloma, these treatments aren’t ready for prime time, said Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.
Transcript
What progress has been made with CAR T treatments in multiple myeloma?
CAR T treatments are really exciting. They’re at the forefront of what’s being studied in myeloma. They’re not quite ready for prime time, yet, because we still don’t know all of the safety or durability of this treatment.
But one of the exciting things is some of the CAR Ts are actually able to kill myeloma that’s been really resistant, and we’re seeing that in some of the early data presented about the patients who had relapsed and refractory myeloma. And this is really important because some of these patients have no other option. So to have something that really eradicates disease for some patients who were really not able to get a response, that’s really encouraging.
But, like I said before, it’s a therapy that’s not available to everyone just yet. It’s still being studied, particularly for safety and now for efficacy. And once that data is more mature—and I would say that would be maybe in the next 1 to 2 years—we’ll be able to better understand where to position that for a myeloma patient.
What novel treatments in development for multiple myeloma are you keeping an eye on?
We’re looking at ways for myeloma to be attacked, for example, using a different protein on the myeloma surface and tagging that with an antibody or making the antibodies work better. For example, we can maybe activate a T cell and tag that and target it toward an antibody that’s targeting a myeloma cell. We can bring the myeloma cell with the T cell together and make the patient’s own immune system kill the myeloma better.
Or maybe there could be some toxin attached to an antibody, so when the antibody goes to the myeloma cell, it is directly toxic to that cell only. So, you can get specific effects on the myeloma cell. So, really targeting the myeloma cell, itself, with the immune system, is some of the things that we’re looking at.
Some of the other exciting drugs are looking at different intracellular mechanisms, combining known ways of resistance, and unmasking ways to get around that with some intracellular small molecule inhibitors.
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CAR T Proves Effective and Safe for Refractory Multiple Myeloma
May 15th 2024Due to increasing reports of multiple myeloma and the emergence of chimeric antigen receptor (CAR) T-cell therapy as a treatment option, these investigators conducted a comprehensive review of the medical literature on the latest CAR T developments in the MM space.
Read More
Patients With MG Report Higher Azathioprine Discontinuation vs Other Immunosuppressants
May 15th 2024Survey data from over 200 patients showed that treatment discontinuation was lower for those taking mycophenolate or methotrexate than for those taking azathioprine for their myasthenia gravis (MG).
Read More